More than 250,000 people suffer from rheumatoid arthritis (RA) in Spain, equivalent to approximately 0.5% of the population. It is a rheumatic disease, autoimmune and chronic causes inflammation in the joints and, despite being extremely disabling, remains a great unknown. To discuss the latest advances in the diagnosis of the disease and its treatment, the Spanish Society of Rheumatology will celebrate these days the Seventh Symposium in Bilbao, on Rheumatoid Arthritis of the SER, the Update Course SER Rheumatoid Arthritis Course and residents Partner AR 3rd and 4th year of BE.
According to Dr. Eduardo Úcar, Honorary President of the Spanish Society of Rheumatology (SER) is essential to update the latest news regarding the approach and management of this disease, as well as new forms of treatment and effects of therapies biological. “It must convey to the public the importance of going to a specialist as soon as possible, as early diagnosis does slow down as far as possible, the progress of the disease and improve the quality of life of the affected”. One of the innovations in this area focuses on the suspension of biologics due to disease remission, emphasizes Dr. Úcar. Specifically, rheumatoid arthritis presents with pain , stiffness, swelling and loss of joint mobility and affects especially the more mobile joints such as hands and feet and wrists, shoulders, elbows, hips and knees.